Confirm fasting for 6-8 hours, review coagulation profile (INR/platelets), obtain informed consent, administer prophylactic antibiotics if indicated, and perform a baseline physical assessment.
Monitor vital signs for 2-4 hours post-procedure, assess for abdominal pain or signs of perforation/pancreatitis, initiate clear liquids once gag reflex returns, and discharge home with instructions to monitor for fever or jaundice.
Comprehensive Clinical Guide: ERCP with Uncovered Self-Expandable Metal Stent (SEMS) Placement
1. Introduction and Clinical Overview
Endoscopic Retrograde Cholangiopancreatography (ERCP) with the placement of an Uncovered Self-Expandable Metal Stent (SEMS) represents a cornerstone intervention in modern interventional gastroenterology and hepatobiliary surgery. This procedure is primarily indicated for the management of malignant biliary obstruction, where external compression or intrinsic luminal narrowing prevents normal bile flow, leading to jaundice, cholangitis, and liver dysfunction.
Unlike plastic stents, which are prone to early occlusion and require frequent replacement, uncovered SEMS provide a larger caliber luminal diameter and a longer patency duration. They are designed to exert constant radial force against the biliary stricture, effectively "opening" the duct and maintaining biliary drainage into the duodenum. This guide serves as an authoritative resource for clinicians, fellows, and medical professionals regarding the technical, clinical, and post-procedural management of this intervention.
2. Technical Specifications and Mechanisms
The Anatomy of the Uncovered SEMS
The "Uncovered" SEMS is a wire-mesh scaffold, typically constructed from Nitinol (a nickel-titanium alloy known for its shape-memory properties).
- Radial Force: The stent is compressed into a delivery catheter and, upon deployment, expands to reach a pre-determined diameter (typically 8mm to 10mm).
- Design Philosophy: The "uncovered" nature of the stent means the metallic mesh is in direct contact with the bile duct wall. This allows for the anchoring of the stent into the tissue, minimizing migration.
- Mechanism of Action: By maintaining a patent channel, the stent facilitates the gravity-fed or physiological flow of bile, bypassing the malignant obstruction.
Comparison Table: Uncovered SEMS vs. Plastic Stents
| Feature | Uncovered SEMS | Plastic Stent |
|---|---|---|
| Luminal Diameter | Large (8-10mm) | Small (7-11.5 Fr) |
| Patency Duration | Long (6–12+ months) | Short (3 months) |
| Migration Risk | Low (due to tissue ingrowth) | Higher |
| Removability | Difficult/Impossible | Easy |
| Primary Use | Unresectable Malignancy | Benign Strictures/Temporary |
3. Clinical Indications and Usage
The decision to place an uncovered SEMS is usually reserved for patients with unresectable, malignant biliary obstruction.
Primary Indications
- Pancreatic Cancer: Specifically for head-of-pancreas tumors causing distal common bile duct (CBD) obstruction.
- Cholangiocarcinoma: For hilar or distal obstructions where surgical resection is contraindicated.
- Metastatic Disease: External compression of the biliary tree due to lymphadenopathy or liver metastases.
- Palliative Care: To resolve obstructive jaundice, pruritus, and cholangitis in patients with limited life expectancy.
Contraindications
- Benign Strictures: Placing an uncovered SEMS in benign conditions (e.g., chronic pancreatitis, post-surgical strictures) is generally contraindicated because tissue ingrowth makes the stent impossible to remove.
- Coagulopathy: Uncorrected INR > 1.5 or platelet count < 50,000/µL.
- Acute Cholangitis (Un-drained): Must be managed with antibiotics and urgent drainage before elective stent placement.
- Anatomic Constraints: Inability to cannulate the papilla or reach the site of obstruction.
4. Pre-Operative Preparation
Success in ERCP is heavily dependent on meticulous pre-procedural planning.
- Laboratory Assessment: CBC, coagulation profile (PT/INR/PTT), liver function tests (LFTs), and serum electrolytes.
- Imaging: Cross-sectional imaging (CT or MRI/MRCP) is mandatory to map the anatomy and determine the precise level of obstruction.
- Antibiotic Prophylaxis: Administration of prophylactic antibiotics (e.g., Ciprofloxacin or Ceftriaxone) is standard to prevent post-ERCP cholangitis.
- NPO Status: Strict NPO (nothing by mouth) for at least 8 hours prior to the procedure.
- Informed Consent: Must include a discussion on the risks of pancreatitis, bleeding, perforation, and the permanent nature of the uncovered stent.
5. The Procedure: Step-by-Step
The procedure is performed under conscious sedation or general anesthesia, depending on institutional protocol and patient complexity.
- Access: The endoscope is advanced to the second portion of the duodenum to visualize the Major Papilla.
- Cannulation: A sphincterotome or cannula is used to gain access to the Common Bile Duct (CBD) under fluoroscopic guidance.
- Cholangiogram: Contrast dye is injected to delineate the biliary anatomy and confirm the length and location of the stricture.
- Guidewire Placement: A 0.035-inch guidewire is passed through the stricture into the intrahepatic ducts.
- Deployment: The uncovered SEMS delivery system is tracked over the guidewire. Under fluoroscopic monitoring, the stent is deployed across the stricture.
- Expansion: Once the sheath is retracted, the stent self-expands. Radiopaque markers on the delivery system assist in precise placement.
- Confirmation: Post-deployment fluoroscopy confirms adequate expansion and positioning.
6. Post-Operative Recovery and Monitoring
Recovery is typically managed in a specialized endoscopy recovery unit.
- Immediate Monitoring: Vital signs are checked every 15 minutes. Focus on signs of perforation (abdominal pain, tachycardia) or hemorrhage (hematemesis, melena).
- Post-ERCP Pancreatitis (PEP) Prevention: Rectal indomethacin is often administered to high-risk patients.
- Diet: Patients are typically allowed to resume a clear liquid diet within 2–4 hours post-procedure, progressing to a regular diet as tolerated.
- Discharge Criteria: Stable vitals, absence of severe abdominal pain, and ability to tolerate oral intake.
7. Potential Complications
Despite the high success rate, ERCP carries inherent risks that must be managed promptly.
| Complication | Estimated Incidence | Mitigation Strategy |
|---|---|---|
| Post-ERCP Pancreatitis | 3% – 10% | Rectal NSAIDs, pancreatic duct stenting |
| Biliary Infection | 1% – 3% | Prophylactic antibiotics |
| Hemorrhage | < 1% | Proper coagulation, sphincterotomy management |
| Perforation | < 0.5% | Gentle technique, expert navigation |
| Stent Occlusion | 10% – 20% (long term) | Tumor ingrowth management |
8. Alternative Treatments
When uncovered SEMS are not appropriate, the following alternatives are considered:
- Plastic Stents: Preferred for benign strictures or when the life expectancy is very short (< 3 months).
- Covered SEMS: Used when there is a high risk of tumor ingrowth or for benign strictures that require eventual removal.
- Percutaneous Transhepatic Cholangiography (PTC): Used when ERCP fails or the anatomy makes the endoscopic approach impossible.
- Surgical Bypass: Choledochojejunostomy may be performed if the patient is a surgical candidate and has a long life expectancy.
9. Frequently Asked Questions (FAQ)
1. Why is the stent called "uncovered"?
The mesh is not lined with a silicone or polyurethane membrane. This allows the tumor to grow through the interstices of the mesh, which acts as an anchor to prevent the stent from migrating.
2. Can the uncovered SEMS be removed later?
Generally, no. Because the tissue grows into the wire mesh, removal is extremely difficult and carries a high risk of damaging the bile duct.
3. How long does an uncovered SEMS last?
Typically, these stents remain patent for 6 to 12 months. However, patency depends on the biology of the tumor and the rate of tissue ingrowth.
4. Will I be under general anesthesia?
This depends on your hospital and your medical history. Many ERCPs are done under moderate (conscious) sedation, but complex cases may require general anesthesia.
5. What are the signs of stent blockage?
Recurrence of jaundice (yellowing of skin/eyes), dark urine, clay-colored stools, itching (pruritus), or fever/chills.
6. Is it normal to have abdominal pain after the procedure?
Mild discomfort is common due to air insufflation. However, severe, persistent, or worsening pain should be reported to the medical team immediately.
7. What happens if the stent gets blocked?
A repeat ERCP may be performed to place a "stent-in-stent" (a second stent inside the first) or to clean the existing stent if possible.
8. Does the stent affect my diet?
Once recovered from the procedure, there are no specific dietary restrictions related to the stent.
9. Can I undergo MRI with a metal stent?
Yes. Most modern biliary stents are made of Nitinol and are considered "MR Conditional." Always inform the imaging facility that you have a biliary stent.
10. How is the success of the procedure measured?
Success is measured by the normalization of bilirubin levels and the resolution of the clinical symptoms (jaundice, pruritus) that prompted the procedure.
10. Conclusion
The placement of an uncovered SEMS via ERCP is a highly effective, minimally invasive solution for malignant biliary obstruction. By providing superior patency and ease of deployment compared to older plastic alternatives, it significantly improves the quality of life for patients facing complex hepatobiliary malignancies. Clinicians must maintain a high index of suspicion for complications and ensure that patient selection remains strictly aligned with the intended use of this permanent, non-removable device. Through precise execution and vigilant post-operative monitoring, the interventional gastroenterologist provides a critical bridge in the palliative management of biliary disease.
